RET and lung cancer: Vepafestinib also inhibited the growth of multiple lung cancer patient-derived cell lines harboring RET fusions with different N-terminal partners (CCDC6, KIF5B, TRIM33) and a RETC634W-mutation-positive MTC cell line.